Skip to main content
. Author manuscript; available in PMC: 2024 Jan 14.
Published in final edited form as: Clin Cancer Res. 2023 Jul 14;29(14):2651–2667. doi: 10.1158/1078-0432.CCR-21-3521

Figure 2. ALK aberrations are common in congenital and pediatric GBMs.

Figure 2.

A. H&E staining showing glioma features. ALK immunohistochemistry (IHC) showing typical 3+ (left top) and 2+ (left bottom) staining appearance; pie chart demonstrating the distribution of ALK IHC scores in the congenital GBM cohort (n = 10). See methods for detail scoring schema.

B. H&E staining and ALK IHC of two illustrative pediatric GBMs scored as focally IHC 3+ (left top) and 2+ (left bottom); pie chart demonstrating the distribution of ALK IHC scores in the infant/pediatric GBM cohort (n = 22).

C. Oncoprint of sequenced GBMs illustrating ALK fusion/amplification is the sole candidate driver alteration in pediatric GBMs. The second lane showed the ALK-positive samples by IHC. Genomic aberrations including fusions (red), focal amplifications (>log 2.0, >10Mb), deletions or mutations (green). The tumors ALK.219, ALK.227 and ALK.228 harbored NTRK3, MET and ROS1 fusions respectively but were negative for ALK fusion.